NCT02184416 2026-02-27
ADONIS
Pfizer
Completed
Clinical Trials
61 trialsNCT01120249 2025-09-16
S0931
SWOG Cancer Research Network
Phase 3 Completed
NCT03324373 2025-04-24
Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)
University of Iowa
Phase 1 Completed
NCT03173560 2025-04-01
Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
Eisai Inc.
Phase 2 Completed
NCT00655655 2024-08-21
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Phase 1 Completed
NCT02599324 2023-11-18
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Pharmacyclics LLC.
Phase 1/2 Completed
NCT02106507 2023-05-26
ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02890069 2023-01-11
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Phase 1 Completed
NCT00805129 2022-11-25
Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00830895 2022-11-09
RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)
Seoul National University Hospital
Phase 2 Completed
NCT03163667 2022-09-15
ENTRATA
Calithera Biosciences, Inc
Phase 2 Completed
NCT01668784 2022-08-09
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
Bristol-Myers Squibb
Phase 3 Completed
NCT02071862 2022-07-20
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
Phase 1 Completed
NCT01034631 2022-07-11
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Hoosier Cancer Research Network
Phase 1/2 Completed
NCT00392821 2022-06-06
Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT01399918 2022-02-01
Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01218555 2022-01-27
Study of Everolimus (RAD001) in Combination With Lenalidomide
Emory University
Phase 1 Completed
NCT02125084 2021-05-04
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
SCRI Development Innovations, LLC
Phase 1 Completed
NCT01865747 2021-04-27
METEOR
Exelixis
Phase 3 Completed
NCT01152801 2020-12-21
Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer
Novartis
Phase 1 Completed
NCT01482156 2020-12-21
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT02077933 2020-12-08
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Novartis
Phase 1 Completed
NCT01051570 2020-12-01
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT01184326 2019-10-02
Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00976755 2019-08-09
Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer
Swiss Cancer Institute
Phase 2 Completed
NCT01206764 2019-06-24
A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
Novartis
Phase 4 Completed
NCT01136733 2019-02-27
A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
Eisai Inc.
Phase 1/2 Completed
NCT02134899 2018-12-10
EVERKYSTE
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT01548807 2018-08-22
Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT00529802 2018-04-25
Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer
University of Chicago
Phase 2 Completed
NCT01107509 2018-04-04
Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers
St. Joseph's Healthcare Hamilton
Phase NA Completed
NCT01259063 2018-03-13
RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00814788 2018-01-10
UCDCC#215
University of California, Davis
Phase 2 Completed
NCT00630344 2017-12-08
RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01266837 2017-11-14
MARC-2
iOMEDICO AG
Phase 4 Completed
NCT00331409 2017-10-26
Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT01514448 2017-07-19
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
Novartis
Phase 4 Completed
NCT01462214 2017-05-10
Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer
Amsterdam UMC, location VUmc
Phase 1/2 Completed
NCT00719264 2017-03-20
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Novartis
Phase 2 Completed
NCT00949949 2017-01-12
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Mayo Clinic
Phase 1 Completed
NCT00903175 2016-11-08
RECORD-3
Novartis
Phase 2 Completed
NCT00688753 2016-09-02
MACS0460
Novartis
Phase 2 Completed
NCT01442090 2016-08-10
Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy
Genentech, Inc.
Phase 2 Completed
NCT01801137 2016-06-21
AFINIVEST
Hopital Foch
Phase 2 Completed
NCT01491672 2016-06-06
RECORD-4
Novartis
Phase 2 Completed
NCT00943956 2016-05-25
Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1 Completed
NCT00459186 2016-05-16
The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT00446368 2016-03-17
RAD001
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00448149 2016-03-17
Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
The Methodist Hospital Research Institute
Phase 1/2 Completed
NCT00303732 2016-03-03
PTK/RAD
Duke University
Phase 1 Completed